Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-11

Clinical Trial Update: Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating baricitinib for treating cutaneous lichen planus has completed, with results posted in June 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Baricitinib (baricitinib)

Snippet

Sponsor: Aaron R. Mangold | Conditions: Cutaneous Lichen Planus | Phase 2 | Status: COMPLETED | Results posted: 2024-06-11